USANA Health Sciences (USNA) Tops Q4 EPS by 43c

USANA Health Sciences (NYSE: USNA) reported Q4 EPS of $1.41, $0.43 better than the analyst estimate of $0.98. Revenue for the quarter came in at $271.3 million versus the consensus estimate of $252.75 million.

“Our fourth quarter results were stronger than expected and allowed us to finish the year strong,” said Kevin Guest, Chief Executive Officer. “Our performance was driven by a better-than-expected response to promotions we offered during the quarter, as well as improved general momentum in many of our markets around the world, including China.

“As we begin fiscal 2020, we believe our business is positioned to deliver solid operating results. However, we acknowledge the evolving situation in China, where our customers, employees, and China’s health officials are responding to the spread of the coronavirus. While the Chinese New Year holiday typically affects our first quarter results, we expect an additional negative impact this year as a result of the coronavirus and the related impact on our business and consumer spending in China. Notwithstanding the expected impact to our near-term results, we remain confident in our China business and our long-term opportunity in this important market.”

GUIDANCE:

USANA Health Sciences sees FY2020 EPS of $4.10-$4.90, versus the consensus of $4.36. USANA Health Sciences sees FY2020 revenue of $1.03-1.13 million, versus the consensus of $1.05 million.

For earnings history and earnings-related data on USANA Health Sciences (USNA) click here.

You May Also Be Interested In

• Tesla touts acceleration of new models, but Q1 results fall short of estimates
• Costar Group (CSGP) Tops Q1 EPS by 3c, Offers Guidance
• Eastgroup Properties (EGP) Tops Q1 EPS by 17c, provides guidance